Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma

PURPOSE: We evaluated the pharmacokinetics (PKs), pharmacodynamics, safety, and efficacy of selinexor, an oral selective inhibitor of nuclear export compound, in patients with advanced soft tissue or bone sarcoma with progressive disease. PATIENTS AND METHODS: Fifty-four patients were treated with o...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Gounder, Mrinal M., Zer, Alona, Tap, William D., Salah, Samer, Dickson, Mark A., Gupta, Abha A., Keohan, Mary Louise, Loong, Herbert H., D’Angelo, Sandra P., Baker, Stephanie, Condy, Mercedes, Nyquist-Schultz, Kjirsten, Tanner, Lanier, Erinjeri, Joseph P., Jasmine, Francis H., Friedlander, Sharon, Carlson, Robert, Unger, Thaddeus J., Saint-Martin, Jean-Richard, Rashal, Tami, Ellis, Joel, Kauffman, Michael, Shacham, Sharon, Schwartz, Gary K., Abdul Razak, Albiruni Ryan
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2016
Aiheet:
Original Reports
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5321073/
https://ncbi.nlm.nih.gov/pubmed/27458288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.67.6346
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia